Status:
COMPLETED
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Orion Corporation, Orion Pharma
Conditions:
Metastatic Prostate Cancer
Eligibility:
MALE
30-55 years
Phase:
PHASE1
Brief Summary
This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as wel...
Eligibility Criteria
Inclusion
- Is a healthy male according to the assessment of the investigator
- Has a body mass index of 18.0 to 32.0 kg/m2
- Has regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day)
Exclusion
- Has the presence or history of clinically significant allergy requiring treatment
- Has a history of adrenal insufficiency
- Has veins not suitable for multiple venipunctures/cannulation
- Has previously taken part in more than 3 radiolabeled drug studies in the last 12 months
- Has donated blood or plasma within the previous 3 months or lost greater than 400 mL of blood
Key Trial Info
Start Date :
September 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 17 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06566989
Start Date
September 19 2024
End Date
October 17 2024
Last Update
October 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Sciences ( Site 0001)
Nottingham, Nottinghamshire, United Kingdom, NG11 6JS